Turn Therapeutics Inc. (NASDAQ:TTRX) Given Consensus Recommendation of “Hold” by Brokerages

Posted by George Bondi on Sep 14th, 2026

Turn Therapeutics Inc. (NASDAQ:TTRX – Get Free Report) has received an average recommendation of “Hold” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $9.00.

A number of brokerages have recently weighed in on TTRX. Wall Street Zen raised Turn Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Zacks Research upgraded Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. Weiss Ratings cut Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. WBB Securities restated a “sell” rating and issued a $10.00 target price on shares of Turn Therapeutics in a report on Monday. Finally, LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th.

View Our Latest Stock Analysis on TTRX

Turn Therapeutics Stock Performance

Shares of TTRX traded up $0.86 during trading hours on Monday, reaching $13.55. 85,580 shares of the company traded hands, compared to its average volume of 55,308. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 8.83. The business has a fifty day moving average price of $9.71 and a 200-day moving average price of $6.28. The stock has a market capitalization of $403.80 million and a P/E ratio of -46.14. Turn Therapeutics has a 12-month low of $2.57 and a 12-month high of $26.50.

Turn Therapeutics (NASDAQ:TTRX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. Equities analysts anticipate that Turn Therapeutics will post -0.4 EPS for the current fiscal year.

Institutional Trading of Turn Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Hodges Capital Management Inc. acquired a new position in Turn Therapeutics during the fourth quarter valued at $39,000. LPL Financial LLC acquired a new stake in shares of Turn Therapeutics during the fourth quarter worth $51,000. Bank of America Corp DE bought a new position in Turn Therapeutics during the second quarter worth about $103,000. Tamar Securities LLC acquired a new position in shares of Turn Therapeutics during the 4th quarter worth about $59,000. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of Turn Therapeutics in the 2nd quarter valued at approximately $119,000.

Turn Therapeutics Company Profile

(Get Free Report)

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.